Topic: Parkinson's disease
UCB partners with Verint Systems to launch a new app for Parkinson’s patients.
AbbVie and Mission Therapeutics inked an R&D pact focused on deubiquitylating enzymes in Alzheimer’s and Parkinson’s disease.
UB-312 prevented the accumulation of misfolded alpha-synuclein proteins in cell and animal models of Parkinson's disease.
Protein clumps that occur in both the gut and the brain could be prime targets for Parkinson's therapies, new research suggests.
Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.
CuraSen Therapeutics has pulled off a $54.5 million series A funding round as it gains big-name backing to help tackle neurodegenerative disorders.
Researchers accidentally reprogrammed mature neurons into dopamine-producing neurons—a discovery that could spark new therapies for brain diseases.
Acorda’s share price took a one-two punch this week, with the FDA extending review of its drug-device treatment for Parkinson’s disease by 3 months.
Kyowa Hakko Kirin has posted a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients.
Acorda's chief technology officer Rick Batycky, Ph.D., is leaving the company next week after four years in the role to head up his own operation.